Data from a post-hoc analysis of the landmark EMPA-REG OUTCOME study show that changes in markers of plasma volume were the main factors causing a 38% decline in the risk of death due to vascular events with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. These findings are published in the February 2018 issue of Diabetes Care.